Activity 5: Achieving health equity to eliminate racial, ethnic, and socioeconomic disparities in HBV- and HCV-associated liver disease

Journal of Family Practice

Volumn 59, Issue SUPPL. 4, 2010, Pages

  El Serag, Hashem ^a   McGlynn, Katherine A ^b   Graham, Garth N ^c   So, Samuel ^d   Howell, Charles D ^e   Fang, Ted ^f   Anderson, Janelle Tangonan ^g   Thiel, Thelma King ^h  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Office of Minority Health   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^f Asian Week Foundation   (United States)

^g National Task Force on Hepatitis B   (United States)

^h Hepatitis Foundation International   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; PEGINTERFERON; RIBAVIRIN;

AFRICAN AMERICAN; AMERICAN INDIAN; ASIAN; CANCER INCIDENCE; CANCER RISK; COMMUNITY CARE; CONFERENCE PAPER; ETHNIC DIFFERENCE; ETHNIC GROUP; FUNDING; GOVERNMENT REGULATION; HEALTH CARE ACCESS; HEALTH CARE DISPARITY; HEALTH CARE DISTRIBUTION; HEALTH CARE QUALITY; HEALTH EDUCATION; HEALTH PROGRAM; HEPATITIS B; HEPATITIS C; HIGH RISK POPULATION; HISPANIC; HUMAN; INFECTION RISK; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MINORITY GROUP; MORTALITY; PATIENT EDUCATION; RACISM; SOCIOECONOMICS; TREATMENT OUTCOME; ARTICLE; ETHNOLOGY; HEALTH CARE DELIVERY; HEALTH DISPARITY; HEALTH PROMOTION; LIVER TUMOR; ORGANIZATION AND MANAGEMENT; RISK FACTOR; UNITED STATES;

CARCINOMA, HEPATOCELLULAR; HEALTH PROMOTION; HEALTH SERVICES ACCESSIBILITY; HEALTH STATUS DISPARITIES; HEPATITIS B; HEPATITIS B, CHRONIC; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; LIVER NEOPLASMS; RISK FACTORS; SOCIOECONOMIC FACTORS; UNITED STATES;

EID: 77951285623     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (32)

1. Rawls RA, Vega KJ. Viral hepatitis in minority America. J Clin Gastroenterol. 2005;39:144-151.
2. Hall-Baker PA, Nieves E Jr, Jajosky RA, et al; Centers for Disease Control and Prevention. Summary of notifiable diseases - United States, 2007. MMWR 2009;56:1-94.
3. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705-714.
4. Centers for Disease Control and Prevention. National Center for Health Statistics. Health, United States, 2009. http://www.cdc.gov/nchs/hus.htm. Accessed December 8, 2009.
5. Wise M, Bialek S, Finelli L, et al. Changing trends in hepatitis C-related mortality in the United States, 1995-2004. Hepatology. 2008;47:1128-1135.
6. US Department of Veterans Affairs. Hepatitis C and Hepatocellular Carcinoma. http://www.hepatitis.va.gov/vahep?page=prtop08-02-kb-01#S2X. Accessed January 22, 2010.
7. El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res. 2007;37 (suppl 2):S88-S94.
8. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27:1485-1491.
9. McGlynn K. Racial, ethnic, and socioeconomic disparities in chronic liver disease and HCC in the US. Presented at: The Dawn of a New Era: Transforming Our Domestic Response to Hepatitis B & C; September 10-11, 2009; Washington, DC.
10. Agency for Healthcare Research and Quality. National healthcare disparities report 2008. http://www.ahrq.gov/qual/nhdr08/Key.htm. Accessed January 21, 2010.
11. Estrada AL. Health disparities among African-American and Hispanic drug injectors - HIV, AIDS, hepatitis B virus and hepatitis C virus: a review. AIDS. 2005;19 (suppl 3):S47-S52.
12. Kanwal F, Hoang T, Spiegel BM, et al. Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatient factors. Hepatology. 2007;46:1741-1749.
13. Bini EJ, Bräu N, Currie S, et al. Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol. 2005;100:1772-1779.
14. Butt AA, Justice AC, Skanderson M, et al. Rate and predictors of treatment prescription for hepatitis C. Gut. 2007;56:385-389.
15. Sloane D, Chen H, Howell C. Racial disparity in primary hepatocellular carcinoma: tumor stage at presentation, surgical treatment and survival. J Natl Med Assoc. 2006;98:1934-1939.
16. Reid AE, Resnick M, Chang Y, et al. Disparity in use of orthotopic liver transplantation among blacks and whites. Liver Transpl. 2004;10:834-841.
17. Moylan CA, Brady CW, Johnson JL, et al. Disparities in liver transplantation before and after introduction of the MELD score. JAMA 2008;300:2371-2378.
18. Davila JA, El-Serag HB. Racial differences in survival of hepatocellular carcinoma in the United States: a population-based study. Clin Gastroenterol Hepatol. 2006;4:104-110; quiz 4-5.
19. Mathur AK, Sonnenday CJ, Merion RM. Race and ethnicity in access to and outcomes of liver transplantation: a critical literature review. Am J Transplant 2009;9:2662-2668.
20. Reid A. Viral hepatitis in African Americans. Curr Hepat Rep. 2008;7:120-126.
21. Harrison P, Beck AJ. Prison and jail inmates at midyear 2005: US Department of Justice. Bureau of Justice Statistics Bulletin; May 2006. NCJ 213133.
22. Rodewald LE, Tan L. Balancing the childhood immunization program with the urgent needs for adult hepatitis B immunization. Public Health Rep. 2007;122(suppl 2):52-54.
23. Flores YN, Yee HF Jr, Leng M, et al. Risk factors for chronic liver disease in Blacks, Mexican Americans, and Whites in the United States: results from NHANES IV, 1999-2004. Am J Gastroenterol. 2008;103:2231-2238.
24. Rodríguez-Torres M. Chronic hepatitis C in minority populations. Curr Hepat Rep. 2008;7:158-163.
25. Conjeevaram HS, Fried MW, Jeffers LJ, et al; Virahep-C Study Group. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology. 2006;131:470-477.
26. Rodriguez-Torres M, Jeffers LJ, Sheikh MY, et al. Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med. 2009;360:257-267.
27. Lin SY, Chang ET, So SK. Why we should routinely screen Asian American adults for hepatitis B: a cross-sectional study of Asians in California. Hepatology. 2007;46:1034-1040.
28. Chao SD, Chang ET, Le PV et al. The Jade Ribbon Campaign: a model program for community outreach and education to prevent liver cancer in Asian Americans. J Immigr Minor Health. 2009;11:281-290.
29. Juon HS, Strong C, Oh TH, et al. Public health model for prevention of liver cancer among Asian Americans. J Community Health. 2008;33:199-205.
30. So S. Community responses and initiatives in HBV Presented at: The Dawn of a New Era: Transforming Our Domestic Response to Hepatitis B & C; September 10-11, 2009; Washington, DC.
31. Centers for Disease Control and Prevention. Screening for chronic hepatitis B among Asian/Pacific Islander Populations - New York City, 2005. MMWR. Recomm Rep. 2006;55:505-509.
32. Chang ET, Sue E, Zola J, et al. 3 For Life: a model pilot program to prevent hepatitis B virus infection and liver cancer in Asian and Pacific Islander Americans. Am J Health Promot. 2009;23:176-181.